<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690155</url>
  </required_header>
  <id_info>
    <org_study_id>18734</org_study_id>
    <nct_id>NCT02690155</nct_id>
  </id_info>
  <brief_title>Real-world Comparative Effectiveness of Rivaroxaban Versus VKA</brief_title>
  <acronym>RIVA-F</acronym>
  <official_title>Real-world Comparative Effectiveness of Rivaroxaban Versus VKA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To obtain a better understanding on the comparative effectiveness of rivaroxaban versus
      VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial
      fibrillation) in a real-life setting
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2016</start_date>
  <completion_date type="Actual">March 1, 2016</completion_date>
  <primary_completion_date type="Actual">March 1, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Hospitalization Events (composite endpoint)</measure>
    <time_frame>Within 2 years of starting treatment</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">38831</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <description>NVAF patients who were initiated on rivaroxaban for stroke prevention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VKA (Vitamin K antagonist)</arm_group_label>
    <description>NVAF patients who were initiated on VKA for stroke prevention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>As prescribed by treating physicians</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA (Vitamin K antagonist)</intervention_name>
    <description>As prescribed by treating physicians</description>
    <arm_group_label>VKA (Vitamin K antagonist)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-valvular atrial fibrillation (NVAF)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NVAF(non-valvular atrial fibrillation) will be defined as the occurrence of 2 or more
             inpatient or outpatient claims with ICD(International Classification of Disease)-9
             427.31 as the diagnosis code at any time in the patient's data history prior to
             inclusion

          -  Patients will be required to have 180 days of enrollment for the assessment of
             baseline characteristics

          -  CHA2DS2-Vasc score â‰¥2 during the 180 days prior to index rivaroxaban use baseline
             period (CHA2DS2-Vasc: Diabetes mellitus; S2: prior Stroke or TIA or Thromboembolism;
             V: Vascular disease; A: Age 65-74 years; Sc: Sex category)

        Exclusion Criteria:

          -  Patients &lt;18 years of age

          -  Patients with valvular AF (Atrial fibrillation)

          -  Pregnancy

          -  Malignant cancers

          -  Transient cause of AF

          -  Patients with venous thromboembolism (pulmonary embolism or deep vein thrombosis)

          -  Patients with major surgery defined as hip or knee replacement

          -  Prescriptions of oral anticoagulants (OACs) (apixaban, warfarin, dabigatran,
             rivaroxaban) before index date

          -  Prescription of more than one OAC on the index date

          -  Patient with any of the events defined in the composite endpoint

               -  Fatal bleeding

               -  Fatal Stroke/Myocardial infarction

               -  Intracranial hemorrhage

               -  Ischemic stroke

               -  Myocardial infarction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2016</study_first_submitted>
  <study_first_submitted_qc>February 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-valvular atrial fibrillation (NVAF)</keyword>
  <keyword>Prevention</keyword>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

